Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic-Reference-Cited by-同舟云学术

Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic

Published:2020-07-04 Issue:3 Volume:190 Page:346-357
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kastritis Efstathios¹^ORCID,Wechalekar Ashutosh²,Schönland Stefan³,Sanchorawala Vaishali⁴^ORCID,Merlini Giampaolo⁵,Palladini Giovanni⁵,Minnema Monique⁶,Roussel Murielle⁷,Jaccard Arnaud⁸,Hegenbart Ute³,Kumar Shaji⁹^ORCID,Cibeira Maria T.¹⁰,Blade Joan¹⁰,Dimopoulos Meletios A.¹^ORCID

Affiliation:

1. Plasma Cell Dyscrasia Unit Department of Clinical Therapeutics National and Kapodistrian University of Athens Athens Greece

2. National Amyloidosis Centre London UK

3. Medical Department V, Amyloidosis Centre University Hospital Heidelberg Heidelberg Germany

4. Amyloidosis Center School of Medicine and Boston Medical Center Boston University Boston MA USA

5. Department of Molecular Medicine Amyloidosis Research and Treatment Center Foundation “Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo” University of Pavia Pavia Italy

6. Department of Hematology UMC Utrecht Cancer Center Utrecht The Netherlands

7. Clinical Hematology IUC Oncopole/CHU Toulouse Toulouse France

8. CHU Poitiers Poitiers France

9. Division of Hematology Department of Internal Medicine Mayo Clinic Rochester MN USA

10. Hematology Department Amyloidosis and Myeloma Unit Hospital Clínic of Barcelona University of Barcelona IDIBAPS Barcelona Spain

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16898

Reference103 articles.